Three of the largest drugmakers in Nigeria saw their combined profit after tax rise by 17 percent from N6.36 billion in the 2022 financial year from N5.42 billion in 2021.
Business expansion activities and the rise in health consciousness among Nigerians boosted their revenue by 23 percent to N80
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
